The present study investigated the influence on disease progression of TP53 alterations in Binet A CLL patients, enrolled in the multicentre prospective observational O-CLL1 trial with a long follow-up (median ~ 7 years). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.